Key contents and precautions for use of dasatinib instructions

Dasatinib (Dasatinib) is a tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). As a targeted therapy drug, dasatinib achieves its therapeutic purpose by inhibiting the activity of BCR-ABL1 tyrosine kinase and preventing the proliferation and spread of tumor cells. In order to ensure the effectiveness and safety of the drug, patients must understand the key information in the instructions in detail and follow the doctor's instructions when using dasatinib.

Important information in the manual

1.Indications: The main indications of dasatinib include the treatment of all stages of chronic myeloid leukemia (CML) (including chronic phase, accelerated phase and blast phase) and acute lymphoblastic leukemia (ALL). It mainly inhibits the proliferation of cancer cells by targeting the BCR-ABL1 fusion gene.

2.Usage and dosage: Dasatinib is usually taken orally, once or twice a day. The specific dosage and treatment plan are adjusted according to the patient's condition and the doctor's recommendations. For CML patients, the recommended initial dose is 100 mg once daily 1 times. For ALL patients, dosage may vary and need to be adjusted based on patient response.

3.Drug ingredients and dosage forms: The common dosage form of dasatinib is tablets, which contain different drug doses. Each dosage of tablets can be adjusted to the patient's specific condition.

4.Adverse reactions: Patients may experience some side effects when using dasatinib. Common side effects include headache, fatigue, nausea, diarrhea, rash, etc. More serious side effects include hematological abnormalities (such as anemia, leukopenia), heart problems (such as heart failure), pulmonary complications (such as interstitial lung disease), etc.

5.Contraindications: Pregnant and breastfeeding women should not use dasatinib. For patients with serious heart disease (such as QT prolongation, heart failure, etc.), special caution is required when using this drug. In addition, patients should consult their doctor when taking other medications to avoid interactions with certain medications.

6.Storage conditions: Dasatinib should be stored in a cool, dry place away from direct sunlight. Medications are usually stored at room temperature and should be kept out of the reach of children.

Special precautions when using dasatinib

1.Heart health monitoring: Dasatinib may cause heart problems, such as heart failure, arrhythmia, etc., especially in patients with pre-existing heart disease. While using the drug, patients should undergo regular cardiac examinations, including electrocardiograms and heart function tests. If symptoms such as chest pain and shortness of breath occur, seek medical attention immediately.

2.Blood monitoring: Because dasatinib may cause hematological abnormalities, such as leukopenia, anemia, etc., patients need to regularly monitor blood routine during treatment, especially in the early stages of treatment. Hematological problems may increase the risk of infection or cause symptoms such as fatigue and weakness, so the dose needs to be adjusted in time or treatment suspended.

3.Liver and kidney function monitoring: Dasatinib has a certain impact on liver and kidney function, which may lead to elevated liver enzymes, renal insufficiency and other problems. Patients should regularly check their liver and kidney function when using the drug, especially for patients with existing liver and kidney diseases. If abnormalities are found, the medication dose may need to be adjusted or an alternative treatment option selected.

4.Interactions with other drugs: Dasatinib may interact with certain drugs, especially with strong CYP3A4 inhibitors or inducers. When using dasatinib, patients should inform their doctor about all medications they are taking, including prescription, over-the-counter, and herbal medicines, to avoid drug interactions.

5.Contraindications during pregnancy and lactation: Dasatinib is potentially harmful to the fetus and pregnant women should avoid using this drug. Dasatinib should be avoided if you are breast-feeding because the drug may be passed to the baby in breast milk, causing potential harm.

6.Dose adjustment and patient individualized treatment: The treatment plan and dose of dasatinib should be adjusted according to the patient's condition, drug resistance and side effects. Individualized treatment is an important means to ensure the safety and effectiveness of drugs. Patients should communicate with their doctors regularly and adjust treatment plans in a timely manner to achieve the best treatment results.

Dasatinib is a targeted drug for the treatment of chronic myelogenous leukemia and acute lymphoblastic leukemia. Although it has shown significant clinical efficacy, during use, patients need to pay special attention to the monitoring of heart, blood, liver and kidney functions. By working closely with their doctor, regularly checking their physical condition and adjusting their dosage, patients can minimize side effects and improve treatment effectiveness.

Reference materials:https://go.drugbank.com/drugs/DB01254